01 Sep 2023 SwiftPharma and AntoXa Corporation sign exclusive collaboration agreement to support the development and commercialization of a plant-made antibody against ricin exposure Member news
17 Jul 2023 argenx reports positive topline data from ADHERE study of VYVGART Hytrulo in patients with chronic inflammatory demyelinating polyneuropathy Member news
10 Jul 2023 Sequana Medical announces first patient enrolled in MOJAVE, a US randomized controlled Phase 1/2a study of DSR® 2.0 for treatment of congestive heart failure Member news
30 Jun 2023 argenx and Zai Lab announce approval of VYVGART® (efgartigimod alfa injection) for generalized myasthenia gravis in China Member news
21 Jun 2023 argenx announces U.S. Food and Drug Administration approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) injection for subcutaneous use in generalized myasthenia gravis Member news
12 Jun 2023 Oxurion finalizes enrollment in KALAHARI Phase 2, Part B trial of novel PKal inhibitor THR-149 in diabetic macular edema Member news
11 May 2023 Mithra announces completion of recruitment in pediatric study of Estelle in adolescent patients Member news
More info? Ellen Telleir Communications Project Manager linkedin.com/in/ellentelleir/ ellen.telleir@biovia.be Contact us
